For patients with multiple sclerosis (MS), the Tisch MS Research Center of New York (MSRCNY) and its affiliated clinical practice, the International Multiple Sclerosis Management Practice, are important centers. They represent one of the few sites worldwide were clinical excellence is paired with cutting-edge research aimed at finding a cure for MS, a disease which affects 400,000 Americans and 2.5 million people worldwide.

In groundbreaking news released January 2016, the Tisch MS Research Center of New York (MSRCNY) announced that it is pursuing a Phase II clinical trial, exploring the use of spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (MSC-NPs) for the treatment of MS.  [Read more…]